Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016374 | 1.00 | TPMT (0.54) | TPMTPOLBKDM4ELMNAXDH | |
| SCHEMBL645817 | 0.90 | VCAM1 (0.55) | TPMTPOLBKDM4ELMNAGFER | |
| SCHEMBL30159180 | 0.86 | MAPT (0.52) | TPMTPOLBKDM4ELMNAGFER | |
| SCHEMBL22081923 | 0.86 | MAPT (0.52) | TPMTPOLBKDM4ELMNAGFER | |
| SCHEMBL31161445 | 0.84 | LMNA (0.53) | TPMTPOLBKDM4ELMNAVCAM1 | |
| SCHEMBL10608607 | 0.84 | LMNA (0.53) | TPMTPOLBKDM4ELMNAVCAM1 | |
| SCHEMBL11598615 | 0.84 | TPMT (0.57) | TPMTPOLBKDM4ELMNAGAA | |
| SCHEMBL31440703 | 0.84 | KDM4E (0.65) | TPMTPOLBKDM4ELMNAXDH | |
| SCHEMBL643856 | 0.84 | KDM4E (0.65) | TPMTPOLBKDM4ELMNAXDH | |
| SCHEMBL22470472 | 0.84 | KMT2A (0.52) | TPMTPOLBKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673439-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673445-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-3919488-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-120020129-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-119431314-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12129267-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024182414-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BIONTECH US INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024180103-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2024-09-06 | — | — | WO | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2017100594-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129267-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | TPMT 3108/4885POLB 652/4885KDM4E 3438/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | TPMT 528/4885POLB 498/4885KDM4E 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.